Although rarely life-threatening, morphea may be accompanied by substantial morbidity. Symptoms of active disease and functional impairment from damage are associated with decreased quality of life.1 Morphea treatment is ideally tailored to disease subtype and severity, with the goal of controlling active disease and preventing further damage. Evidence-based treatment in morphea has traditionally been limited in light of the rarity of the condition and a lack of standardized outcome measures.2 However, over the last 10 years, the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) has emerged as a useful outcome measure in morphea research given its ease of use and ability to help differentiate disease activity (erythema, induration at edge, and/or progression) from damage (atrophy, dyspigmentation, and/or sclerosis).3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cruz-Diaz CN, Haemel AK. At the Leading Edge in Morphea—New Insights Into Disease Course and Management Options. JAMA Dermatol. 2020;156(5):495–496. doi:10.1001/jamadermatol.2020.0033
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: